- Home
- ABVC vs IXHL Comparison
ABVC vs IXHL Comparison
Compare ABVC & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ABVC | IXHL |
|---|---|---|
| Founded | 2015 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6M | 37.0M |
| IPO Year | 2009 | 2024 |
Fundamental Metrics
Financial Performance| Metric | ABVC | IXHL |
|---|---|---|
| Price | $1.04 | $2.93 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 149.6K | 145.4K |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.14 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $509,589.00 | $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.88 | $0.16 |
| 52 Week High | $3.39 | $6.39 |
Technical Indicators
Market Signals| Indicator | ABVC | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 37.18 | 41.30 |
| Support Level | $0.96 | $2.77 |
| Resistance Level | $1.15 | $3.68 |
| Average True Range (ATR) | 0.10 | 0.17 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 14.29 | 33.87 |
Price Performance
Historical ComparisonAbout ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.